Proteomics Share Purchase Plan
Proteomics Share Purchase Plan (SPP) Now Open
We have launched a Share Purchase Plan (SPP), seeking to raise up to A$5 million to support the next phase of the Company's commercialisation strategy.
Eligible shareholders are invited to participate in the SPP at an issue price of $0.10 per share, representing a 12.2% discount to the 5-day volume weighted average price as at market close on Friday 30 October.
Funds raised will support commercial execution, clinical and reimbursement programs, laboratory capacity and preparations for US market entry.
Applications and payment must be received by 25 November 2026, unless the offer timetable changes.
SPP Information & Resources
04 Nov 2026
Investor Webinar Presentation
"Proteomics has entered an exciting new phase. In recent months we have secured our national Healius distribution partnership, commenced the Australian rollout of PromarkerD and PromarkerEso, advanced PromarkerEndo towards launch and continued to build the clinical, operational and reimbursement foundations needed to support long-term growth. With three clinically validated tests targeting significant unmet medical needs, and a planned pathway into the US market, we believe the Company is now positioned to translate years of scientific development into commercial outcomes."
- David Morris
CEO & Managing Director